1. Mechanisms underlying age-associated exacerbation of pulmonary veno-occlusive disease
- Author
-
Prabhakar, Amit, Wadhwa, Meetu, Kumar, Rahul, Ghatpande, Prajakta, Gandjeva, Aneta, Tuder, Rubin M, Graham, Brian B, Lagna, Giorgio, and Hata, Akiko
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Rare Diseases ,Lung ,Cardiovascular ,2.1 Biological and endogenous factors ,Animals ,Rats ,Pulmonary Veno-Occlusive Disease ,Male ,Protein Phosphatase 1 ,eIF-2 Kinase ,Disease Models ,Animal ,Mitomycin ,Eukaryotic Initiation Factor-2 ,Vascular Remodeling ,Phosphorylation ,Age Factors ,Aging ,Hypertrophy ,Right Ventricular ,Humans ,Rats ,Sprague-Dawley ,Cardiovascular disease ,Cell stress ,Hypertension ,Therapeutics ,Vascular biology ,Biomedical and clinical sciences ,Health sciences - Abstract
Pulmonary veno-occlusive disease (PVOD) is a rare but severe form of pulmonary hypertension characterized by the obstruction of pulmonary arteries and veins, causing increased pulmonary artery pressure and leading to right ventricular (RV) heart failure. PVOD is often resistant to conventional pulmonary arterial hypertension (PAH) treatments and has a poor prognosis, with a median survival time of 2-3 years after diagnosis. We previously showed that the administration of a chemotherapy agent mitomycin C (MMC) in rats mediates PVOD through the activation of the eukaryotic initiation factor 2 (eIF2) kinase protein kinase R (PKR) and the integrated stress response (ISR), resulting in the impairment of vascular endothelial junctional structure and barrier function. Here, we demonstrate that aged rats over 1 year exhibit more severe vascular remodeling and RV hypertrophy than young adult rats following MMC treatment. This is attributed to an age-associated elevation of basal ISR activity and depletion of protein phosphatase 1, leading to prolonged eIF2 phosphorylation and sustained ISR activation. Pharmacological blockade of PKR or ISR mitigates PVOD phenotypes in both age groups, suggesting that targeting the PKR/ISR axis could be a potential therapeutic strategy for PVOD.
- Published
- 2024